Literature DB >> 23509504

Glycemic control in community-dwelling patients with type 2 diabetes.

Yazid N Al Hamarneh, Meagen Rosenthal, Ross T Tsuyuki.   

Abstract

Entities:  

Year:  2012        PMID： 23509504      PMCID： PMC3567550          DOI： 10.3821/145.2.cpj68

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  7 in total

1.  Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study).

Authors:  Stewart B Harris; Jean-Marie Ekoé; Yola Zdanowicz; Susan Webster-Bogaert
Journal:  Diabetes Res Clin Pract       Date:  2005-10       Impact factor: 5.602

2.  A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).

Authors:  Ross T Tsuyuki; Jeffrey A Johnson; Koon K Teo; Scot H Simpson; Margaret L Ackman; Rosemarie S Biggs; Andrew Cave; Wei-Ching Chang; Vladimir Dzavik; Karen B Farris; Donna Galvin; William Semchuk; Jeff G Taylor
Journal:  Arch Intern Med       Date:  2002-05-27

3.  A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.

Authors:  H C Gerstein; J-F Yale; S B Harris; M Issa; J A Stewart; E Dempsey
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

Review 4.  Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review.

Authors:  Deborah P Wubben; Eva M Vivian
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

5.  Independent pharmacist prescribing in Canada.

Authors:  Michael R Law; Tracey Ma; Judith Fisher; Ingrid S Sketris
Journal:  Can Pharm J (Ott)       Date:  2012-01

6.  Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain.

Authors:  Sebastián R Martínez Pérez; Pedro D Armando; Andrea C Molina Guerra; Mercé Martí Pallarés; Fernando Martínez Martínez
Journal:  Pharm World Sci       Date:  2008-12-09

7.  A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN).

Authors:  Donna L McLean; Finlay A McAlister; Jeffery A Johnson; Kathryn M King; Mark J Makowsky; Charlotte A Jones; Ross T Tsuyuki
Journal:  Arch Intern Med       Date:  2008-11-24
  7 in total
  5 in total

1.  HbA1c testing in the community pharmacy: A new strategy to improve care for patients with diabetes.

Authors:  John Papastergiou; Amy Rajan; Artemis Diamantouros; John Zervas; Justin Chow; Peter Tolios
Journal:  Can Pharm J (Ott)       Date:  2012-07

2.  Point-of-Care HbA1c Testing with the A1cNow Test Kit in General Practice Dental Clinics: A Pilot Study Involving Its Accuracy and Practical Issues in Its Use.

Authors:  Shiela M Strauss; Mary Rosedale; Michael A Pesce; Caroline Juterbock; Navjot Kaur; Joe DePaola; Deborah Goetz; Mark S Wolff; Dolores Malaspina; Ann Danoff
Journal:  Point Care       Date:  2014-12

3.  Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the RxEACH study.

Authors:  Yazid N Al Hamarneh; Karissa Johnston; Carlo A Marra; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2019-06-10

4.  Real-world implementation of diabetes management by pharmacists: The RXING Practice Tool.

Authors:  Yazid N Al Hamarneh; Hiroshi Okada; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2021-04-23

5.  Pharmacist intervention for glycaemic control in the community (the RxING study).

Authors:  Yazid N Al Hamarneh; Theresa Charrois; Richard Lewanczuk; Ross T Tsuyuki
Journal:  BMJ Open       Date:  2013-09-24       Impact factor: 2.692
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.